ERBB2 and breast cancer: Moreover, ZNF695 expression was higher in more aggressive basal‐like and HER2‐enriched breast cancers associated with early relapse and poor clinical outcome (Kennecke et al., 2010; Sorlie et al., 2001, 2003).